It is worth noting that a few PI3K inhibitors have been endorsed by the US Food and Drug Administration (USFDA) for the treatment of advanced metastatic breast cancer as well as chronic lymphocytic leukemia and small lymphocytic lymphomas [211]. This evidence concerns the gene PIK3CA and B-cell chronic lymphocytic leukemia.